Watson aims for August launch of EC
This article was originally published in The Tan Sheet
Executive Summary
The maker of the just-approved Next Choice emergency contraceptive, a generic of Teva's Plan B (levonorgestrel), applies to make the drug available for nonprescription sale upon the expiration of Teva's market exclusivity Aug. 24. A spokeswoman said June 29 that Watson Pharmaceuticals is confident FDA will approve the Next Choice nonprescription application, but does not know whether the decision will come before Plan B loses exclusivity. FDA likely will apply to non-Rx levonorgestrel generics the same age restriction on pharmacy-only sales it imposed on Plan B (1"The Tan Sheet" June 29, 2009). Watson reserves the right to later seek universal OTC sales status, the spokeswoman said
You may also be interested in...
Generic Rx Plan B Approval Points To Possible OTC Equivalents In Near Future
FDA's approval of a generic prescription-only Plan B makes a nonprescription generic of the emergency contraceptive likely, potentially as early as August
Indo-German Collaboration Delivers Novel Diabetic Foot Ulcer Treatment
Centaur-CytoTools introduces novel topical treatment for diabetic foot ulcers in India, for which they see limited direct competition and hope to change the way the difficult-to-treat diabetes complication is managed. Phase III studies are ongoing in Europe.
QUOTED. 1 October 2020. Stephen Hahn.
The head of the US Food and Drug Administration praised the life-saving work of device center staff in response to the coronavirus pandemic.
Need a specific report? 1000+ reports available Buy Reports
Register for our free email digests: